Myocardial InfarctionNCT07696390
The Effect of Virtual Reality Application Diagnosed With Myocardial Infarction
A study testing virtual reality glasses in people with Myocardial Infarction, run by Yuzuncu Yil University at 1 site in Turkey (Türkiye).
Trial summary
This study was designed to investigate the effects of VR (virtual reality) glasses on vital signs and anxiety in conscious patients diagnosed with myocardial infarction and admitted to the cardiology intensive care unit. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Myocardial Infarction
- What is being tested?
- virtual reality glasses
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 10 Jul 2026to 18 Sep 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- The patient is in intensive care.
- The patient has been diagnosed with myocardial infarction.
- The patient is between 18 and 70 years old.
- The patient is conscious.
- The patient is oriented and cooperative.
- The patient volunteers to participate in the study.
Show all 11Show fewer
- The patient is open to communication.
- The patient agrees to participate in the study.
- The patient has no mental, visual, auditory, or speech impairment.
- The patient has undergone stent placement.
- The patient has STEMI.
Who cannot join
- The patient has a psychiatric disorder.
- The patient has any communication impairment.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site, 1 recruiting
- Recruiting
SBU Van Training and Research Hospital
Van, 65
About this study
Official title: The Effect of Virtual Reality on Vital Signs and Anxiety in Myocardial Infarction Patients Admitted to Cardiology Intensive Care Unit: A Randomized Controlled Study.
This study was designed to investigate the effects of VR (virtual reality) glasses on vital signs and anxiety in conscious patients diagnosed with myocardial infarction and admitted to the cardiology intensive care unit.
Read the detailed description
This study was designed to investigate the effects of VR (virtual reality) glasses on vital signs and anxiety in conscious patients with myocardial infarction (MI) admitted to the cardiology intensive care unit. Studies examining the psychological (anxiety) and physiological (vital signs) effects of VR application on MI patients in cardiology intensive care units are quite limited. In this context, this study aims to examine the effects of VR glasses application on the vital signs (blood pressure, heart rate, SPO2, respiratory rate) and anxiety levels of MI patients in intensive care, within the framework of a randomized experimental design. The data obtained are expected to make significant contributions to the integration of technological interventions into cardiovascular disease management.
- Conditions
- Myocardial Infarction
- Being tested
- virtual reality glasses
- Keywords
- Myocardial infarction, virtual reality, vital signs, stress
- Medical subject headings
- Myocardial Infarction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
virtual reality glassesOther
Participants will be shown a video with nature images through virtual reality glasses, and their vital signs and anxiety levels will be measured.
| Study group | Role | What they receive |
|---|---|---|
| EXPERIMENTAL GROUP | Experimental | Participants will be shown a video with nature images through virtual reality glasses, and their vital signs and anxiety levels will be measured. Receives: Other: virtual reality glasses |
| CONTROL GROUP | No intervention | In this group, vital signs and anxiety levels will be measured as pre-test and post-test without any intervention. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Anxiety Level
The patient's anxiety level will be measured using the State Anxiety Scale (STAI Form TX-1).
Measured: Periprocedural
Vital Signs - Blood pressure measurements (SBP, DBP)
Blood pressure measurements (SBP, DBP)
Measured: Periprocedural
Vital Signs- heart rate
heart rate will be taken.
Measured: Periprocedural
Vital Signs - respiratory rate per minute
respiratory rate per minute will be taken.
Measured: Periprocedural
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jul 2026
- Study start10 Jul 2026
- Primary completion18 Sep 2026 (estimated)
- Study completion18 Sep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Myocardial InfarctionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Yuzuncu Yil University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Yavuz Uren, Yuzuncu Yil University
- Investigators
- Yavuz Uren, Asst.Prof, Study chair, Van Yuzuncu Yil Universty
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07696390
- Sponsor's protocol ID
- Myocardial Infarction - VR
- Status last verified
- Jul 2026
- First submitted
- 24 Jun 2026
- Last updated
- 13 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Virtual Reality on Vital Signs and Anxiety in Myocardial Infarction Patients Admitted to Cardiology Intensive Care Unit: A Randomized Controlled Study.
- ClinicalTrials.gov ID
- NCT07696390
- Acronym / sponsor ID
- Myocardial Infarction - VR
- Conditions
- Myocardial Infarction
- Keywords
- Myocardial infarction, virtual reality, vital signs, stress
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Yuzuncu Yil UniversityUniversity, hospital or other
- Study start
- 10 Jul 2026 (actual)
- Primary completion
- 18 Sep 2026 (estimated)
- Study completion
- 18 Sep 2026 (estimated)
- First posted
- 10 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study was designed to investigate the effects of VR (virtual reality) glasses on vital signs and anxiety in conscious patients diagnosed with myocardial infarction and admitted to the cardiology intensive care unit.
Detailed description
This study was designed to investigate the effects of VR (virtual reality) glasses on vital signs and anxiety in conscious patients with myocardial infarction (MI) admitted to the cardiology intensive care unit. Studies examining the psychological (anxiety) and physiological (vital signs) effects of VR application on MI patients in cardiology intensive care units are quite limited. In this context, this study aims to examine the effects of VR glasses application on the vital signs (blood pressure, heart rate, SPO2, respiratory rate) and anxiety levels of MI patients in intensive care, within the framework of a randomized experimental design. The data obtained are expected to make significant contributions to the integration of technological interventions into cardiovascular disease management.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| EXPERIMENTAL GROUP | Experimental | Other: virtual reality glassesParticipants will be shown a video with nature images through virtual reality glasses, and their vital signs and anxiety levels will be measured. |
| CONTROL GROUP | No intervention | –In this group, vital signs and anxiety levels will be measured as pre-test and post-test without any intervention. |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- The patient is in intensive care.
- The patient has been diagnosed with myocardial infarction.
- The patient is between 18 and 70 years old.
- The patient is conscious.
- The patient is oriented and cooperative.
Key exclusion criteria (2 listed)
- The patient has a psychiatric disorder.
- The patient has any communication impairment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| virtual reality glassesParticipants will be shown a video with nature images through virtual reality glasses, and their vital signs and anxiety levels will be measured. | Other | EXPERIMENTAL GROUP |
Primary outcome
Anxiety Level
Time frame: Periprocedural
The patient's anxiety level will be measured using the State Anxiety Scale (STAI Form TX-1).
Vital Signs - Blood pressure measurements (SBP, DBP)
Time frame: Periprocedural
Blood pressure measurements (SBP, DBP)
Vital Signs- heart rate
Time frame: Periprocedural
heart rate will be taken.
Vital Signs - respiratory rate per minute
Time frame: Periprocedural
respiratory rate per minute will be taken.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Myocardial Infarction
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
Active, not recruitingObservational study
A Longitudinal Cohort Study to Evaluate Cardiovascular Risk Factors and Disease in Haiti
Hypertension, Diabetes
Active, not recruitingPhase 3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Primary Prevention of Atherosclerotic Cardiovascular Disease
Enrolling by invitation
The DANE-HEART Trial - Computed Tomography Coronary Angiography for Primary Prevention
Coronary Atherosclerosis and Other Heart Disease, Cardiovascular Diseases
Not yet recruitingObservational study
Elicit Drugs in Myocardial Infarction
Young Patients With Acute Myocardial Infarction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Yavuz Uren, Asst.Prof study chair
Van Yuzuncu Yil Universty
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing virtual reality glasses in people with Myocardial Infarction, run by Yuzuncu Yil University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yavuz Uren, Asst.Prof. (+905065961050, yavuzuren@yyu.edu.tr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Anxiety Level (time frame: Periprocedural). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jul 2026.